Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | TYK2 | P29597 | 14/20 | 0.51 |
| ▸ | JAK2 | O60674 | 12/20 | 0.51 |
| ▸ | JAK1 | P23458 | 7/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29164538 | 0.90 | TYK2 (0.57) | RAB9ATYK2JAK2JAK1CYP3A4 | |
| SCHEMBL759767 | 0.83 | CCNA2 (0.58) | RAB9ATYK2JAK2JAK1GAA | |
| SCHEMBL29164864 | 0.81 | PDE10A (0.51) | RAB9ATAS1R3TAS1R1TAS1R2HPGD | |
| SCHEMBL30822730 | 0.81 | PDE10A (0.51) | RAB9ATAS1R3TAS1R1TAS1R2HPGD | |
| SCHEMBL29164888 | 0.81 | TYK2 (0.42) | RAB9ATYK2CYP3A4TAS1R3TAS1R1 | |
| SCHEMBL706559 | 0.81 | MEN1 (0.63) | RAB9ATYK2JAK2JAK1GAA | |
| SCHEMBL29164555 | 0.79 | L3MBTL1 (0.43) | RAB9ATYK2JAK2JAK1TAS1R3 | |
| SCHEMBL7175136 | 0.78 | CYP1A2 (0.58) | RAB9ACYP3A4GAA | |
| SCHEMBL3421073 | 0.77 | NPC1 (0.63) | RAB9AJAK2JAK1L3MBTL1KMT2A | |
| SCHEMBL3928941 | 0.77 | TTR (0.37) | RAB9ATYK2JAK2JAK1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| WO-2010122089-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | ORAI1, TRPV1, CACNA1E | RAB9A 1678/4885TYK2 1534/4885JAK2 2500/4885 |
| US-20100273744-A1 | COMPOUNDS | LTC4S, HRH4, HRH2 | RAB9A 1472/4885TYK2 1914/4885JAK2 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.